Kazia Therapeutics SP ADR

View in Terminal

Loading quotes...

Forecast

The analysts' average price target is €30.20 (+368.94%). The median is €28.70 (+345.65%).

Buy	3
Hold	0
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2013, Kazia Therapeutics SP ADR has already paid €3.04 in dividends. The last payout was in January 2013.

Financials

In the last quarter, Kazia Therapeutics SP ADR had revenue of €0 and net profit of -€7.01m

(EUR)	December 2025	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-7.01m	-
EBITDA	-7.56m	-

Fundamentals

Metric	Value
Market capitalization	€11.74m
Number of shares	1.62m
52-week high/low	€15.60 - €4.36
Dividends	No
Beta	2.36
P/E ratio	-1.11
PEG ratio	-0.01
P/B ratio	0.78
P/S ratio	947.76

Company profile

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.